<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26878">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083315</url>
  </required_header>
  <id_info>
    <org_study_id>CP130-1003</org_study_id>
    <nct_id>NCT02083315</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Explore the Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare TRV130 to placebo and morphine to learn about its effects
      on pain relief and side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This  study will explore the pharmacokinetics, pharmacodynamics (PD), safety and
      tolerability of TRV130.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cold Pain Test</measure>
    <time_frame>8 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilatory Response to Hypercapnia</measure>
    <time_frame>4 hours postdose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry</measure>
    <time_frame>8 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>TRV130 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 1.5 mg IV x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 3 mg IV x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 4.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 4.5 mg IV x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine 10 mg IV x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose 5% in water IV x 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130 1.5 mg</intervention_name>
    <description>TRV130 1.5 mg IV x 1 dose</description>
    <arm_group_label>TRV130 1.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130 3 mg</intervention_name>
    <description>TRV130 3 mg IV x 1 dose</description>
    <arm_group_label>TRV130 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130 4.5 mg</intervention_name>
    <description>TRV130 4.5 mg IV x 1 dose</description>
    <arm_group_label>TRV130 4.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 10 mg</intervention_name>
    <description>Morphine 10 mg IV x 1 dose</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextrose 5% in water IV x 1 dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Healthy adult males age 18 - 50 years, BMI 19-32 kg/m2

          -  Acceptable duration of cold pain test results at screening

        Exclusion Criteria:

          -  Clinically significant medical illness or physical exam findings

          -  Active dermatological conditions or skin trauma on the non-dominant hand, or
             peripheral vascular disease

          -  Partial blindness, keratoconus, nystagmus or any other ophthalmic condition which
             could interfere with pupillometry

          -  Use of tobacco or nicotine within 6 months prior to screening

          -  History of recent (within 6 months) drug or alcohol abuse, as defined in DSM-IV-TR
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David G Soergel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trevena Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute pain, analgesia, respiratory drive, ventilator response to hypercapnia, pupillometry</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
